1/1
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-In-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
media
posted on 2022-01-11, 12:48 authored by Adis Journals on behalf of, Dominic Brittain, Peter D’Andrea, Emilie Gruen, Motoi Hosoe, Devendra JainDevendra Jain, Juergen Jauernig, Abhijit Pethe, Emil Scosyrev, Ana-Maria Tanase, Hanns-Christian TillmanArticle full text
The above talking head video represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2022.
